Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects

ConclusionMultiple daily oral doses of 40  mg omeprazole had no significant effect on the pharmacokinetics of a single oral dose of 100 mg roxadustat. Roxadustat was considered safe and well tolerated when administered alone or in combination with multiple daily oral doses of 40 mg omeprazole in healthy subjects.
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research

Related Links:

Anemia is a condition characterized by a deficiency of red blood cells (RBCs) or hemoglobin (Hb), resulting in a diminished capacity of the blood to carry and deliver oxygen to tissues and organs (Abbasi et al., 2014). Anemia is often multifactorial in etiology and may be patient- (e.g., iron-deficiencies, vitamin deficiencies), disease- (e.g., bone marrow diseases, chronic diseases, hemorrhage), or anticancer treatment- (e.g., chemotherapy, radiotherapy, precision therapies) related (Crathorne et al., 2016).
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research
The first biosimilar to epoetin alfa for patients with anemia from chronic kidney disease, chemotherapy, or zidovudine treatment for HIV infection has receivedFDA approval.
Source: JAMA - Category: General Medicine Source Type: research
AbstractAn iron scarcity often occurs in chronic kidney disease (CKD). Neutrophil gelatinase-associated lipocalin (NGAL), a biomarker of acute kidney injury, is associated with iron metabolism. The present study determined the association between serum NGAL and iron status in chronic kidney disease with anemia. A total of 154 adult CKD patients were divided into anemia and without anemia groups. The anemia groups were further subdivided into two groups based on the presence or absence of iron deficiency, defined as a transferrin saturation (TSAT)  
Source: Clinical and Experimental Medicine - Category: Research Source Type: research
Conditions:   Anemia;   Renal Insufficiency, Chronic Intervention:   Drug: Mircera Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
A combination of safety concerns and labeling changes impacted use of erythropoiesis-stimulating agents (ESAs) in renal anemia. Data regarding contemporary utilization in pre-dialysis chronic kidney disease (C...
Source: BMC Nephrology - Category: Urology & Nephrology Authors: Tags: Research article Source Type: research
On June 7, 2018, the Food and Drug Administration approved methoxy polyethylene glycol-epoetin beta (Mircera, Vifor Pharma Inc.) for the treatment of pediatric patients 5 to 17 years of age on hemodialysis who are converting from another ESA after...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
CONCLUSIONS: The complication rate is higher in transfused patients. The number of complications rises linearly with the number of transfusions. Infection rate is also higher after a transfusion. Efforts should be made to reduce the transfusion rate. PMID: 29914043 [PubMed - as supplied by publisher]
Source: Technology and Health Care - Category: Medical Devices Authors: Tags: Technol Health Care Source Type: research
Purpose of review Historically, the identity of O2-sensing renal erythropoietin (Epo)-producing (REP) cells was a matter of debate. This review summarizes how recent breakthroughs in transgenic mouse and in-situ hybridization techniques have facilitated sensitive and specific detection of REP cells and accelerated advancements in the understanding of the regulation of renal Epo production in health and disease. Recent findings REP cells are a dynamically regulated unique subpopulation of tubulointerstitial cells with features of fibroblasts, pericytes and neurons. Under normal conditions, REP cells are located in the ...
Source: Current Opinion in Nephrology and Hypertension - Category: Urology & Nephrology Tags: RENAL PATHOPHYSIOLOGY: Edited by Orson W. Moe and Susan Quaggin Source Type: research
Anemia is a common and debilitating manifestation of chronic kidney disease (CKD). Data from two clinical trials in patients with anemia of CKD were used to assess the measurement properties of the Medical Out...
Source: Health and Quality of Life Outcomes - Category: International Medicine & Public Health Authors: Tags: Research Source Type: research
CONCLUSIONS Anemia was more common in diabetic CKD patients. Diabetes mellitus was independently associated with iron deficiency. Surprisingly, diminished iron availability was not more frequent in diabetic patients. The physio-pathological mechanisms that could explain these findings remain to be elucidated.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
More News: Anemia | Chronic Kidney Disease | Drugs & Pharmacology | Electrocardiogram | Laboratory Medicine | Omeprazole | Prilosec | Study | Urology & Nephrology